Physician profile
John Croke
NPI 1013994649
$2,491.13
in general payments reported to CMS, 2019-2025
20 companies · $1,357 in 2025
The $1,357 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $144 · 2022: $169 · 2023: $174 · 2024: $647 · 2025: $1,357.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,994 · Education: $185.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,993.58 |
| Education | $184.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $708.52 | 2022-2025 | Adbry, Anzupgo |
| Janssen Biotech, INC. | $382.60 | 2021-2025 | Tremfya, Stelara, Simponi |
| Abbvie INC. | $251.55 | 2022-2025 | Skyrizi |
| Ucb, INC. | $246.56 | 2024-2025 | Bimzelx |
| Novartis Pharmaceuticals Corporation | $154.59 | 2022-2025 | |
| Acadia Pharmaceuticals INC | $123.50 | 2021 | |
| Amgen INC. | $95.85 | 2025 | Otezla, Otezla |
| Sun Pharmaceutical Industries INC. | $73.87 | 2023-2025 | Winlevi, Absorica Ld |
| E.R. Squibb & Sons, L.L.C. | $62.38 | 2022-2024 | Sotyktu |
| Dermavant Sciences, INC. | $60.64 | 2024 | Vtama |
| Galderma Laboratories, L.P. | $52.57 | 2024-2025 | Aklief, Oracea, Nemluvio |
| Arcutis Biotherapeutics, INC. | $40.73 | 2024-2025 | Zoryve |
| Genzyme Corporation | $36.46 | 2023 | |
| Organon LLC | $34.50 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $33.99 | 2024 | Dupixent |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Helsinn Therapeutics (U.S.), INC. | $33.87 | 2025 | Valchlor |
| Incyte Corporation | $28.15 | 2025 | Opzelura |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.02 | 2023 | Spevigo |
| Lilly USA, LLC | $22.52 | 2022 | |
| Pfizer INC. | $22.26 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Croke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.